Reply to: Laffon and Marthan "FDG PET for therapy monitoring in Hodgkin's and non-Hodgkin's lymphomas: qPET versus rPET"
Eur J Nucl Med Mol Imaging
.
2017 Dec;44(13):2331-2332.
doi: 10.1007/s00259-017-3826-x.
Epub 2017 Sep 22.
Authors
Regine Kluge
1
,
Sally Barrington
2
,
Lars Kurch
3
,
Dirk Hasenclever
4
Affiliations
1
Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstrasse 18, 04103, Leipzig, Germany.
[email protected]
.
2
PET Imaging Centre, King's College London and Guy's, King's Health Partners, St. Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK.
3
Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstrasse 18, 04103, Leipzig, Germany.
4
Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Härtelstrasse 16-18, 04107, Leipzig, Germany.
PMID:
28939986
DOI:
10.1007/s00259-017-3826-x
No abstract available
Publication types
Letter
Comment
MeSH terms
Fluorodeoxyglucose F18*
Hodgkin Disease
Humans
Lymphoma, Non-Hodgkin*
Positron-Emission Tomography
Substances
Fluorodeoxyglucose F18